|  Help  |  About  |  Contact Us

Publication : Myelin dysfunction drives amyloid-β deposition in models of Alzheimer's disease.

First Author  Depp C Year  2023
Journal  Nature Volume  618
Issue  7964 Pages  349-357
PubMed ID  37258678 Mgi Jnum  J:339557
Mgi Id  MGI:7520331 Doi  10.1038/s41586-023-06120-6
Citation  Depp C, et al. (2023) Myelin dysfunction drives amyloid-beta deposition in models of Alzheimer's disease. Nature 618(7964):349-357
abstractText  The incidence of Alzheimer's disease (AD), the leading cause of dementia, increases rapidly with age, but why age constitutes the main risk factor is still poorly understood. Brain ageing affects oligodendrocytes and the structural integrity of myelin sheaths(1), the latter of which is associated with secondary neuroinflammation(2,3). As oligodendrocytes support axonal energy metabolism and neuronal health(4-7), we hypothesized that loss of myelin integrity could be an upstream risk factor for neuronal amyloid-beta (Abeta) deposition, the central neuropathological hallmark of AD. Here we identify genetic pathways of myelin dysfunction and demyelinating injuries as potent drivers of amyloid deposition in mouse models of AD. Mechanistically, myelin dysfunction causes the accumulation of the Abeta-producing machinery within axonal swellings and increases the cleavage of cortical amyloid precursor protein. Suprisingly, AD mice with dysfunctional myelin lack plaque-corralling microglia despite an overall increase in their numbers. Bulk and single-cell transcriptomics of AD mouse models with myelin defects show that there is a concomitant induction of highly similar but distinct disease-associated microglia signatures specific to myelin damage and amyloid plaques, respectively. Despite successful induction, amyloid disease-associated microglia (DAM) that usually clear amyloid plaques are apparently distracted to nearby myelin damage. Our data suggest a working model whereby age-dependent structural defects of myelin promote Abeta plaque formation directly and indirectly and are therefore an upstream AD risk factor. Improving oligodendrocyte health and myelin integrity could be a promising target to delay development and slow progression of AD.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

21 Bio Entities

Trail: Publication

0 Expression